NCT03151057View on ClinicalTrials.gov

Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

June 20, 2022

Study Completion Date

July 20, 2022

Conditions
B Cells-TumorsB Cell Chronic Lymphocytic LeukemiaFollicular LymphomaMantle Cell LymphomaLarge B-Cell Diffuse Lymphoma of Bone (Diagnosis)
Interventions
DRUG

Idelalisib 100 MG

100mg BID beginning on day 90 (+/- 10days) and continuing until day 270 post transplant.

DRUG

Placebo Oral Tablet

placebo

Trial Locations (1)

21205

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER